Published February 1, 2021
Business First reported that a COVID-19 vaccine developed by UB and Buffalo-based startup POP Biotechnologies has entered human clinical trials in South Korea.
The vaccine is being commercialized in partnership with EuBiologics, a publicly traded health sciences firm based in South Korea. POP Biotechnologies President Jonathan Smyth was a UB student in 2015 when he co-founded the company with UB researcher Jonathan Lovell, SUNY Empire Innovation Associate Professor of biomedical engineering.
Read the story here (subscription required).
